Structured around redefining point-of-care testing, General Fluidics Corporation is an in vitro diagnostic company spun out of the Massachusetts General Hospital Center for Technology Development. The firm's vitro diagnostic platform is intended to offer end-to-end, fully integrated modular IVD platform for performing a growing array of blood and urine tests. The company's platform uses a patented hybrid hardware architecture, fluidics, and optoelectronic technologies to go beyond test results to deliver complete diagnostic information sets at the point of care, enabling physicians to improve the treatment of Neonatal and Pediatric Patients.
